seasonal split influenza vaccine
Biological0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
NCT Number: NCT00556062
To evaluate the safety and immunogenicity of the three consecutive lots of an seasonal split influenza vaccine Anflu in adults, a randomized, double-blind and controlled clinical trial was conducted in 560 subjects in Tianjin City of China.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 4
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
Time frame: 0, 21 days
Time frame: within 3 days after vaccination
Sinovac Biotech Co., Ltd
Industry
The Clinical Trial for Three Consecutive Lots of Influenza Split Vaccine Anflu by Randomized, Double-Blind and Controlled Design
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01191853
Healthy Volunteers, Infections
Bethesda, Maryland, United States
View Trial DetailsNCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07737106
Infections, Influenza
Bayan Nur, Inner Mongolia, China
View Trial DetailsNCT06518577
Infections, Influenza
Phoenix, Arizona, United States
View Trial Details